2023-508124-36-00CompletedPhase 1
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Feb 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- First submitted
- 17 Apr 2024
- Start date
- 10 May 2024
- Lead sponsor
- Genentech Inc.
- Diseases
- Metastatic breast cancer
- EU CT number
- 2023-508124-36-00
- EudraCT number
- 2016-003022-17
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 41
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Completed |
| Hospital Clinico Universitario de Valencia | Valencia | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.